Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma

Journal of the National Cancer Institute

Volumn 104, Issue 21, 2012, Pages 1673-1679

  Jalili, Ahmad ^a   Wagner, Christine ^a   Pashenkov, Mikhail ^a   Pathria, Gaurav ^a   Mertz, Kirsten D ^a   Widlund, Hans R ^a   Lupien, Mathieu ^a   Brunet, Jean Philippe ^a   Golub, Todd R ^a   Stingl, Georg ^a   Fisher, David E ^a   Ramaswamy, Sridhar ^a   Wagner, Stephan N ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2C; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ASSAY; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARTIC ACID; BENZAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GLUTAMIC ACID; GLYCINE; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOCYTES; MELANOMA; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-JUN; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; VALINE; VIRAL VACCINES;

EID: 84869034673     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs373     Document Type: Article

References (31)

1. Chapman PB, Hauschild A, Robert C, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
3. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-599.
4. Cuevas BD, Abell AN, Johnson GL. Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene. 2007;26(22):3159-3171.
5. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
6. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-3096.
7. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968- 972.
8. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
9. Jané-Valbuena J, Widlund HR, Perner S, et al. An oncogenic role for ETV1 in melanoma. Cancer Res. 2010;70(5):2075-2084.
10. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-868.
11. Lopez-Bergami P, Huang C, Goydos JS, et al. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 2007;11(5):447-460.
12. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen- activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995;92(17):7686-7689.
13. Ham J, Babij C, Whitfield J, et al. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron. 1995;14(5):927-939.
14. Hennigan RF, Stambrook PJ. Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes. Mol Biol Cell. 2001;12(8):2352-2363.
15. Quereda V, Martinalbo J, Dubus P, Carnero A, Malumbres M. Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression. Oncogene. 2007;26(55):7665-7674.
16. Holland EA, Schmid H, Kefford RF, Mann GJ. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer. 1999;25(4):339-348.
17. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147.
18. Maelandsmo GM, Holm R, Fodstad O, Kerbel RS, Flørenes VA. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol. 1996;149(6):1813-1822.
19. Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature. 2005;433(7027):764-769.
20. Matsuzaki Y, Takaoka Y, Hitomi T, Nishino H, Sakai T. Activation of protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c). Oncogene. 2004;23(31):5409-5414.
21. Carroll JS, Meyer CA, Song J, et al. Genomewide analysis of estrogen receptor binding sites. Nat Genet. 2006;38(11):1289-1297.
22. Sotillo R, García JF, Ortega S, et al. Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci USA. 2001;98(23):13312-13317.
23. Hacker E, Muller HK, Irwin N, et al. Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Res. 2006;66(6):2946-2952.
24. Halaban R, Cheng E, Zhang Y, Mandigo CE, Miglarese MR. Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1. Oncogene. 1998;16(19):2489-2501.
25. Pennati M, Campbell AJ, Curto M, et al. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005;4(9):1328-1337.
26. Brooks EE, Gray NS, Joly A, et al. CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation. J Biol Chem. 1997;272(46):29207-29211.
27. Kubo A, Nakagawa K, Varma RK, et al. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999;5(12):4279-4286.
28. Zhu G, Conner SE, Zhou X, et al. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003;46(11):2027-2030.
29. Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor GDC- 0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009;69(7):3042-3051.
30. Sebolt-Leopold JS, Dudley DT, Herrera R, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5(7):810-816.
31. Duncia JV, Santella JB III, Higley CA, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett. 1998;8(20):2839-2844.